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Abstract: The development of chronic kidney disease (CKD) following an episode of acute kidney
injury (AKI) is an increasingly recognized clinical problem. Inhibition of toll-like receptor 4 (TLR4)
protects renal function in animal models of AKI and has become a viable therapeutic strategy in AKI.
However, the impact of TLR4 inhibition on the chronic sequelae of AKI is unknown. Consequently, we
examined the chronic effects of TLR4 inhibition in a model of ischemic AKI. Mice with a TLR4-deletion
on a C57BL/6 background and wild-type (WT) background control mice (C57BL/6) were subjected
to bilateral renal artery clamping for 19 min and reperfusion for up to 6 weeks. Despite the acute
protective effect of TLR4 inhibition on renal function (serum creatinine 1.6˘ 0.4 mg/dL TLR4-deletion
vs. 2.8 ˘ 0.3 mg/dL¨WT) and rates of tubular apoptosis following ischemic AKI, we found no
difference in neutrophil or macrophage infiltration. Furthermore, we observed significant protection
from microvascular rarefaction at six weeks following injury with TLR4-deletion, but this did not
alter development of fibrosis. In conclusion, we validate the acute protective effect of TLR4 signal
inhibition in AKI but demonstrate that this protective effect does not mitigate the sequential fibrogenic
response in this model of ischemic AKI.
Keywords: toll-like receptor 4; acute kidney injury; ischemia-reperfusion; fibrosis
1. Introduction
Acute kidney injury (AKI) is a commonly encountered clinical entity with significant acute
morbidity and mortality [1–6]. In addition to the acute consequences associated with an episode of AKI,
there is growing evidence that maladaptive repair following AKI ushers in the development of chronic
kidney disease (CKD) in patients that survive an episode of AKI [7–10]. The mechanisms associated
with dysfunctional repair following AKI are not well characterized, although the development of
interstitial fibrosis is a common final signature.
Toll-like receptors (TLRs) are a superfamily of transmembrane receptors that detect their respective
ligands through molecular pattern recognition and play a central role in mammalian innate immunity.
However, TLRs are expressed in cells other than the traditional cellular constituents of the innate
immune system. Moreover, endogenous non-microbial ligands known as damage-associated molecular
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patterns (DAMPs) that are released during tissue injury can activate TLRs. Consequently, TLRs may
serve as important monitors of tissue damage and modulators of disease in a variety of conditions
including kidney disease [11]. Toll-like receptor 4 (TLR4), the receptor for endotoxin, is known to be
expressed on kidney tubular epithelial cells as well as kidney microvascular endothelial cells [12,13].
Importantly, it has been demonstrated that DAMP activation of TLR4 on both kidney tubular epithelial
cells and kidney microvascular endothelial cells promotes acute tubular injury and kidney dysfunction
in ischemic AKI [13–16].
Recent investigations have suggested that the role of TLR4 activation extends beyond the acute
phase of injury in various models of kidney disease. Indeed, TLR4 has been implicated in the
modulation of kidney fibrosis and the development of chronic kidney disease (CKD) following acute
injury. Inhibition of TLR4 signaling mitigates the fibrotic response in mouse models of folic acid
nephropathy, 5/6th nephrectomy with concomitant continuous angiotensin infusion, and unilateral
ureteral obstruction [17–20].
In this study, we examine the effects TLR4 signaling on the development of kidney fibrosis in
a mouse model of ischemic AKI. Similar to previous studies, we find that the functional deletion of
TLR4 provides acute protection following ischemic injury. In contrast, this acute protection did not
translate into diminished fibrosis six weeks after injury despite a significant protection of microvascular
rarefaction. These studies suggest that the role of TLR4 signaling may have disparate outcomes
depending on the initial injurious event.
2. Results
2.1. Functional Deletion of TLR4 Confers Acute Protection in a Model of Ischemic AKI
As mentioned above, previous studies have demonstrated that the functional deletion of TLR4
confers protection in a murine model of ischemic AKI [13,14]. For our studies, we used a mouse
with a spontaneous deletion in the Tlr4 coding sequence such that no mRNA or protein is expressed
(B6.B10ScN-Tlr4lps´del/JthJ) that has been backcrossed into C57BL/6 for at least five generations.
Consistent with previous studies, we observed that B6.B10ScN-Tlr4lps´del/JthJ mice (henceforth called
TLR4-deletion mice) were protected from injury in a model of ischemic AKI. Mean serum creatinine
determined 24 h after a 19-min bilateral renal artery clamp was 1.6 ˘ 0.4 mg/dL in the TLR4-deletion
mice as compared to 2.8 ˘ 0.3 mg/dL in C57BL/6 background mice (henceforth called WT mice;
Figure 1A). In addition, TLR4-deletion mice demonstrated a significant reduction in tubular apoptosis,
particularly proximal tubular cell apoptosis, as demonstrated by the mean TUNEL-positive tubular
cells/field (12.8˘ 5.0/field) following ischemic kidney injury as compared to WT mice (26.2˘ 4.5/field;
Figure 1B–F).
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Figure 1. Deletion of TLR4 confers acute protection in a model of ischemic AKI. (A) Mean serum 
creatinine values (±SD) at 24 h following a 19-min bilateral renal artery clamp in background  
control (WT) and TLR4-deletion (TLR4 KO) mice. Representative images (60×) of TUNEL staining are 
shown for background control (WT; B,C) and TLR4-deletion (TLR4 KO; D,E) mice at 24 h following  
a 19-min bilateral renal artery clamp; Panels B and D are composite images of TUNEL (red), DAPI 
(blue), and tubular auto-fluorescence (green); Panels C and E are fields identical to the adjacent 
composite field demonstrating TUNEL staining alone. Quantitation of TUNEL positive tubular cells 
at 24 h is demonstrated in panel F (mean TUNEL-positive tubular cells/field ±SD; 5–7 fields/animal;  
n = 4, * p < 0.05). TUNEL-positive tubular cells were counted by a blinded observer. Scale bar = 50 µm. 
2.2. Functional Deletion of TLR4 Did Not Significantly Alter the Early Inflammatory Response in a Mouse 
Model of Ischemic AKI 
In view of the role that TLR4 plays in activating the innate inflammatory response and the role 
that  inflammation plays in the pathogenesis of ischemic AKI [21], we next examined the number of 
resident tissue inflammatory cells following ischemic injury. Interestingly, we did not observe a 
significant difference in the number of neutrophils (GR-1 positive cells, leukocyte esterase positive 
cells) or macrophages (F4/80 positive cells) in TLR4-deletion mice compared to WT mice 24 h after 
ischemic injury (Figure 2). 
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Figure 1. Deletion of TLR4 confers acute protection in model of ischemic AKI. (A) Mea serum
creatinine values (˘SD) at 24 h f llowing a 19-min bilateral renal artery clamp in background control
(WT) and TLR4-deletion (TLR4 KO) mice. Representative images (60ˆ) of TUNEL staining are shown
for background control (WT; B,C) and TLR4-deletion (TLR4 KO; D,E) mice at 24 h following a 19-min
bilateral renal artery clamp; Panels B and D are composite images of TUNEL (red), DAPI (blue),
and tubular auto-fluorescence (green); Panels C and E are fields identical to the adjacent composite
field demonstrating T EL staining alone. Quantitation of TUNEL positive tubular cells at 24 h is
demonstrated in panel F (mean TUNEL-positive tubular cells/field ˘SD; 5–7 fields/animal; n = 4,
* p < 0.05). TUNEL-positive tubular cells were counted by a blinded observer. Scale bar = 50 µm.
2.2. Functional Deletion of TLR4 Did Not Sig ifi antly Alter the Early Inflammatory Re po se in a Mouse
Model of Ischemic AKI
In view of the role that TLR4 plays in activating the innate inflammatory response and the role
that inflammation plays in the pathogenesis of ischemic AKI [21], we next exa ined the number
of resident tissue inflammatory cells following ischemic injury. Interestingly, we did not observe
a significant difference in the number of neutrophils (GR-1 positive cells, leukocyte esterase positive
cells) or macrophages (F4/80 positive cells) in TLR4-deletion mice compared to WT mice 24 h after
ischemic injury (Figure 2).
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Figure 2. Deletion of TLR4 did not significantly alter the early inflammatory response in a mouse 
model of ischemic AKI. Panel A demonstrates representative Gr-1 staining (brown, indicated by 
arrows) for WT and TLR4-deletion (TLR4 KO) mice at 24 h following a 19-min bilateral renal artery 
clamp. Hematoxylin (blue) was used as a counterstain. Non-specific staining of some tubules was 
noted; Panels B and C show quantitation of nucleated, non-tubular Gr-1-positive cells/field and 
leukocyte esterase-positive cells/field (images not shown) in kidneys from the two groups at 24 h 
following a 19-min bilateral renal artery clamp (mean Gr-1+ or leukocyte esterase+ nucleated, 
non-tubular cells/field ±SD; 5–7 fields/animal; n = 4); Panel D demonstrates representative F4/80 
staining (brown, indicated by arrows) for WT and TLR4-deletion (TLR4 KO) mice at 24 h following a 
19-min bilateral renal artery clamp. Hematoxylin (blue) was used as a counterstain. Non-specific 
staining of some tubules was noted; Panel E shows quantitation of nucleated, non-tubular 
F4/80-positive cells/field in kidneys from the two groups at 24 h following a 19-min bilateral  
renal artery clamp (mean F4/80+ nucleated, non-tubular cells/field ±SD; 5–7 fields/animal; n = 4). 
Scale bar = 40 µm. 
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Consequently, we next evaluated the impact of TLR4 deletion on microvascualr density six weeks 
after an episode of ischemic AKI. Microvascular density, as determined by % area of cablin 
immunostaining [25,28], was better preserved after ischemic injury in the TLR4-deletion mice  
(16.9% ± 5.2%) as compared to the WT mice (7.7% ± 2.4%; Figure 3). 
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WT mice (0.60% ± 0.38%). In addition, fibronectin an extracellular matrix protein that can serve as a 
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TLR4-deletion mice (15.4% ± 7.4%) as compared to the WT mice (11.1% ± 6.2%; Figure 4). 
Figure 2. Deletion of TLR4 did not significantly alter the early inflammatory response in a mouse
model of ischemic AKI. Panel A demonstrates representative Gr-1 staining (brown, indicated by arrows)
for WT and TLR4-deletion (TLR4 KO) mice at 24 h following a 19-min bilateral renal artery clamp.
Hematoxylin (blue) was used as a counterstain. Non-specific staining of some tubules was noted;
Panels B and C show quantitation of nucleated, non-tubular Gr-1-positive cells/field and leukocyte
esterase-positive cells/field (images not shown) in kidneys from the two groups at 24 h following
a 19-min bilateral renal artery clamp (mean Gr-1+ or leukocyte esterase+ nucleated, non-tubular
cells/field ˘SD; 5–7 fields/animal; n = 4); Panel D demonstrates representative F4/80 staining (brown,
indicated by arrows) for WT and TLR4-deletion (TLR4 KO) mice at 24 h following a 19-min bilateral
renal artery clamp. Hematoxylin (blue) was used as a counterstain. Non-specific staining of some
tubules was noted; Panel E shows quantitation of nucleated, non-tubular F4/80-positive cells/field
in kidneys from the two groups at 24 h following a 19-min bilateral renal artery clamp ( ean F4/80+
nucleated, non-tubular cells/field ˘SD; 5–7 fields/animal; n = 4). Scale bar = 40 µm.
2.3. Functional Deletion of TLR4 Preserved icrovascular i ll i i e of Ische ic AKI
Endothelial injury and the loss of microvasc l r sit f ll i g an episode of ischemic
AKI [22–25] has been associated with persistent re al y oxia [26] t at ca sher in the development
and the progression of AKI to CKD [22,27]. TLR4 activation on kidney microvascular endothelial cells
contributes to injury and the overall decrement in function during ischemic AKI [16]. Consequently, we
next evaluated the impact of TLR4 deletion on microvascualr density six weeks after an episode of
ischemic AKI. Microvascular density, as determined by % area of cablin immunostaining [25,28], was
better preserved after ischemic injury in the TLR4-deletion mice (16.9% ˘ 5.2%) as compared to the
WT mice (7.7% ˘ 2.4%; Figure 3).
2.4. Functional Deletion of TLR4 Did Not Significantly Alter the Development of Fibrosis Following an Episode
of Ischemic AKI
To further evaluate the consequence of TL 4- l ti r i elae of ischemic AKI, we
examined the fibrogenic res se at six eeks following injury. Despite the acute protective effect
of TLR4-deletion in this model of ischemic AKI and the mitigation of microvascular loss six weeks
following injury, the degree of fibrosis at six weeks follo ing injury as deter ined by Masson’s
trichrome was not significantly different (Figure 4) between TLR4-deletion mice (0.75% ˘ 0.60%) and
WT mice (0.60% ˘ 0.38%). In addition, fibronectin an extracellular matrix protein that can serve as
a nidus for fibrosis in the kidney [29–32] was not significantly different six weeks after injury in the
TLR4-deletion mice (15.4% ˘ 7.4%) as compared to the WT mice (11.1% ˘ 6.2%; Figure 4).
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Figure 3. Deletion of TLR4 preserved microvascular density following an episode of ischemic AKI.
Panel (A) demonstrates representative images of cablin immunostaining for WT and TLR4-deletion
(TLR4 KO) mice at six weeks following a 19-min bilateral renal artery clamp; Panel (B) shows
quantitation of cablin immunostaining (percent total area staining positive for cablin/field ˘SD;
5–7 fields/animal; n = 4; * p < 0.05). Scale bar = 50 µm.
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Figure 4. Deletion of TLR4 did not significantly alter the development of fibrosis following an episode
of ischemic AKI. Panel (A) demonstrates representative trichrome images for WT and TLR4-deletion
(TLR4 KO) mice at six weeks following a 19-min bilateral renal artery clamp; scale bar = 100 µm;
Panel (B) shows quantitation of collagen/fibrosis (blue) on trichrome stained images (percent total
area staining blue/field ˘SD; 5–7 fields/animal; n = 4); Panel (C) demonstrates representative images of
fibronectin immunostaining for WT and TLR4-deletion (TLR4 KO) mice at six weeks following a 19-min
bilateral renal artery clamp; Scale bar = 50µm; Panel (D) shows quantitation of fibronectin immunostaining
on (percent total area staining positive for fibronectin/field ˘SD; 5–7 fields/animal; n = 4).
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3. Discussion
Several studies have substantiated that activation of TLR4 signaling promotes acute injury in
ischemic AKI [13,14,16,33]. Studies in animal models of kidney transplant-associated ischemia-reperfusion
injury and human kidney transplant-associated delayed graft function have further supported this
finding [34]. Our findings in this study further validate the importance of TLR4 signaling in ischemic
AKI. Similar to previous studies, we demonstrate that TLR4-deletion mitigates functional impairment
(serum creatinine) and tubular apoptosis following acute ischemic kidney injury. Interestingly, despite
the protective effect of TLR-deletion, we did not observe a significant decrease in either neutrophil
or macrophage accumulation at 24 h following injury. This observation contrasts with prior studies
of TLR4-deletion in a mouse model of ischemic AKI [13,14]. Only nucleated interstitial cells that
had immunostaining with the antibody to identify neutrophils or macrophages were counted in our
study, whereas all cells staining positive with the selected antibody were counted in prior studies.
This distinction in quantitative approach, in light of the apparent nonspecific tubular epithelial cell
staining of each antibody demonstrated by us and in previous studies, may partially explain the
difference in findings for both neutrophil and macrophage accumulation. In addition, the kinetics
of macrophage infiltration from prior studies demonstrate a difference between TLR4-deficient and
WT mice that is smallest at 24 h, the time point examined in our study, and largest at five days after
injury [13]. Accordingly, our findings in general underscore the significance of early, non-inflammatory
cell TLR4 activation in the pathophysiology of AKI demonstrated by others [13,35,36] and suggest
that the cellular context of TLR4 activation may be an important determinant of outcome following
a particular insult.
Given the acute protective effect of TLR4-deletion that we observed in ischemic AKI, it was
not surprising to find that microvascular integrity was better maintained following injury in the
TLR4-deficient mice. However, our finding that acute protection and diminished microvascular
rarefaction did not translate into reduced fibrosis was unanticipated provided chronic hypoxia is
believed to be one of the drivers for kidney fibrosis [37,38]. Inhibition of TLR4 signaling has generally
been shown to attenuate fibrosis in rodent models of fibrotic kidney disease [17,18,20], although this
is not a universal finding [39]. Adding to this complexity is that, in at least one study, fibrosis was
diminished despite enhanced tubular injury [17], contrary to general intuition. Our observation that
tubular injury was attenuated without altering long-term fibrosis may be a reflection of the fact that
minimal fibrosis occurred with this model as compared to the more fibrotic models such as UUO.
Giving credence to this notion is the finding in a prior study that despite the increase in fibrosis
following 5/6ths nephrectomy, there was no difference in fibrosis between WT and TLR4-deficient
mice [18]. Only after adding the chronic infusion of angiotensin II to the 5/6ths nephrectomy model
as an additional provocative measure to increase the overall fibrogenic response was a difference in
fibrosis observed between WT and TLR4-deficient mice.
Of note, we have previously reported discordance between microvascular rarefaction and
fibrosis [23,40]. The observation of this discordance may not be unexpected given the number of posited
mechanisms leading to increased kidney fibrosis following injury [41,42]. Furthermore, plausible
mechanisms for how TLR4 activation contributes to kidney fibrosis have support in the literature, and
most evoke some aspect of inflammation. Consequently, since we did not observe any difference in
the acute cellular inflammatory response between TLR4-deletion mice and WT mice in our model,
this may partially explain why we did not observe differences in fibrosis. Lastly, variation in the
susceptibility to fibrosis of background strains in these models may be a more mundane explanation to
the lack of difference in fibrosis observed. Germane to this point is that many of the studies examined
TLR4-deficiency on a C3H background, whereas this study as well as another study [39], demonstrating
no difference in fibrosis, utilized a mouse with TLR4-deficiency on a C57BL/6 background.
In conclusion, we demonstrate that TLR4-deficiency diminishes acute tubular injury and organ
dysfunction without significantly modifying inflammatory cell infiltration in an animal model of
ischemic AKI. This acute protection is associated with preserved microvascular integrity but does not
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alter fibrosis at six weeks after injury. The outcome of TLR4 inhibition following acute ischemic injury
to the kidney may be dependent on the context and cellular origin of TLR4 activation and further work
is needed to clarify the benefit of TLR inhibition on the chronic outcomes of ischemic AKI.
4. Experimental Section
4.1. Animals and Experimental Models
All animal protocols were approved by the Indiana University Institutional Animal Care
Committee and conform to the NIH Guide for the Care and Use of Laboratory Animals.
B6.B10ScN-Tlr4lps´del/JthJ (TLR4-deficient) and C57BL/6 (WT background control) male mice
weighing 20–25 grams (10–12 weeks) were obtained from Jackson Laboratory (Bar Harbor, Maine,
ME, USA). Bilateral renal artery clamp surgery was performed following induction of anesthesia
with 5% isoflurane and maintenance of anesthesia with 1.5% isoflurane and buprenorphine HCL
(0.01 mg/kg) subcutaneously. Core body temperature (37 ˝C) of the mice was maintained by placement
on a homeothermic surgical pad thoughout the surgical procedure. The renal pedicles were isolated
through a midline incision, and bilateral renal ischemia was induced by clamping the renal pedicles
for 19 min with microaneurysm clamps. Reperfusion of the kidneys was monitored visually following
removal of the microaneurysm clamps. Five hundred microliters of prewarmed (37 ˝C) sterile saline
was instilled into the peritoneum just prior to closing the abdominal wound. Animals recovered
on a homeothermic surgical pad until the righting reflex was restored. An identical procedure was
followed with the exception of immediate release of the microaneurysm clamps in sham animals.
Reperfusion time was 24 h prior to euthanasia for the examination of acute tissue changes or six weeks
prior to euthanasia for the examination of chronic tissue changes . Kidneys were harvested at the time
of euthanasia and subsequently processed for histopathology studies as described elsewhere in this
section. Measurement of serum creatinine concentrations was performed at the University of Texas
Southwestern O’Brien Kidney Research Core Center, Dallas, TX, USA.
4.2. Histopathology and Microscopy
Kidneys were rapidly perfused fixed with either 100% methanol (cablin staining only) or
4% paraformaldehyde at the time of euthanasia Kidney tissues were subsequently processed
for immunostaining or standard histochemistry. Immunostaining was performed with primary
antibodies to cablin (rabbit anti-human polyclonal IgG) [43], fibronectin (rabbit anti-rat polyclonal
IgG; MD Biosciences, St. Paul, MN, USA), Gr-1 (NIMP-R14; Abcam, Cambridge, MA, USA), or
F4/80 (Clone CI:A3-1; AbD Serotec, Raleigh, NC, USA). Secondary antibodies conjugated with Texas
Red or horseradish peroxidase were purchased from Jackson Immunoresearch Laboratories, West
Grove, PA, USA. Kidney tissue sections from sham animals and animals undergoing renal ischemia
were incubated with secondary antibodies in the absence of primary antibodies as negative controls.
Staining for leukocyte esterase was performed using a naphthol AS-D chloroacetate (specific esterase)
kit (Sigma-Aldrich, St. Louis, MO, USA) on paraffin-embedded tissue as per the manufacturer’s
instructions. Trichrome staining was performed using standard histochemistry procedures by the
Indiana University Histopathology Lab.
Confocal immunofluorescent images of kidney tissue sections were collected at 60ˆ magnification
using a LSM-510 Zeiss confocal microscope (Peabody, MA, USA) or Olympus FV1000 confocal
microscope (Center Valley, PA, USA). Trichrome-stained images and immunohistochemistry images
of kidney tissue sections were obtained at 10ˆ and 40ˆ magnification respectively with a Nikon
Microphot-SA equipped with SPOT RT Slider camera (Diagnostic Instruments. Inc.; Melville, NY,
USA). Metamorph software (Universal Imaging, West Chester, PA, USA) was used to determine the
percent of total area staining positive for fibrosis (trichrome), cablin, or fibronectin. Cells staining
positive for TUNEL and nucleated interstitial cells staining positve for F4/80, GR-1, and leukocyte
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esterase in each field were manually counted. Tissue scoring and tissue cell counts were quantified by
a blinded individual. Five to seven images were collected of a kidney from each animal.
4.3. Statistical Analysis
Data were analyzed for statistical significance using ANOVA and pairwise t-tests or a nested ANOVA
for nested data within a study subject. All data are reported as means with SD. Significance was set at
p < 0.05.
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